Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients
Condition(s) studied
Study summary
Primary Objective:
To develop a thrombotic event risk assessment model integrating serum biomarkers (TM, TAT, t-PAIC, PIC) with clinical data, systematically compare its predictive performance across healthy populations, vascular surgery patients with acute thrombosis, and dialysis patients, and evaluate its predictive advantages over the Padua Prediction Score and D-dimer.
Secondary Objective:
To investigate the expression profiles of these four thrombotic biomarkers in different populations and their associations with thrombotic event types and clinical contexts (e.g., duration of dialysis, anticoagulation regimens), identifying independent risk factors and underlying mechanisms to provide a scientific foundation for stratified thrombotic risk management and personalized intervention strategies.
Eligibility
Primary outcome measure(s)
- thrombosis outcome in dialysis patients — 1 years
1. Incidence of radiologically confirmed thrombosis Definition: Thrombus definitively visualized by ultrasonography, CT pulmonary angiography, or MRI venography. 2. Incidence of clinically suspected thrombosis with imaging support Definition: Clinical presentation (e.g., limb swelling, pain, respiratory distress) with positive imaging findings. 3. Incidence of laboratory-supported thrombosis with imaging evidence Definition: Elevated D-dimer levels + positive imaging findings + exclusion of alternative diagnoses.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital | Shanghai | Shanghai Municipality |
More Ai Peng trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07098676 on ClinicalTrials.gov ↗ ← All trials in China